Sox2: A possible driver of the basal-like phenotype in sporadic breast cancer

Modern Pathology

Volumn 20, Issue 4, 2007, Pages 474-481

  Rodriguez Pinilla, Socorro M ^a,b   Sarrio, David ^a   Moreno Bueno, Gema ^a   Rodriguez Gil, Yolanda ^c   Martinez, Miguel A ^c   Hernandez, Lucia ^c   Hardisson, David ^d   Reis Filho, Jorge S ^b   Palacios, Jose ^a,e  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Basal like phenotype; Immunohistochemistry; Node negative breast carcinomas; SOX2; Tissue microarray

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; TRANSCRIPTION FACTOR SOX2; VIMENTIN;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; STEM CELL; TISSUE MICROARRAY;

BREAST NEOPLASMS; FEMALE; HMGB PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS, BASAL CELL; PHENOTYPE; SEX-DETERMINING REGION Y PROTEIN; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33947587857     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800760     Document Type: Article

References (76)

1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-752.
2. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874.
3. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-8423.
4. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003;100:10393-10398.
5. Gusterson BA, Ross DT, Heath VJ, et al. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res 2005;7:143-148.
6. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterisation of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-5374.
7. Abd El-Rehim DM, Ball G, Pinder SE, et al. Highthroughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005;116:340-350.
8. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004;203:661-671.
9. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19:264-271.
10. van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;161:1991-1996.
11. Banerjee S, Reis-Filho JS, Ashley S, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 2006;59:729-735.
12. Gamallo C, Moreno-Bueno G, Sarrio D, et al. The prognostic significance of P-cadherin in infiltrating ductal breast carcinoma. Mod Pathol 2001;14:650-654.
13. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-5685.
14. Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 2006;12:1533-1539.
15. Palacios J, Benito N, Pizarro A, et al. Anomalous expression of P-cadherin in breast carcinoma. Correlation with e-cadherin expression and pathological features. Am J Pathol 1995;146:605-612.
16. Rakha EA, Putti TC, Abd El-Rehim DM, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 2006;208:495-506.
17. Tsuda H, Takarabe T, Hasegawa F, et al. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 2000;24:197-202.
18. Fulford LG, Easton DF, Reis-Filho JS, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006;49:22-34.
19. Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006;49:10-21.
20. Jacquemier J, Padovani L, Rabayrol L, et al. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol 2005;207:260-268.
21. Laakso M, Loman N, Borg A, et al. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol 2005;18:1321-1328.
22. Foulkes WD, Brunet JS, Stefansson IM, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid- microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 2004;64:830-835.
23. Turner N, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006;25:5846-5853.
24. Palacios J, Honrado E, Osorio A, et al. Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2004;96:712-714; author reply 4.
25. Robson ME, Chappuis PO, Satagopan J, et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004;6:R8-R17.
26. Chappuis PO, Goffin J, Wong N, et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 2002;39:608-610.
27. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4:814-819.
28. Turner N, Reis-Filho JS, Russel AM, et al. BRCA1 down-regulation in sporadic basal-like breast cancer. Oncogene 2006;1-7.
29. Graham V, Khudyakov J, Ellis P, et al. Sox2 functions to maintain neural progenitor identity. Neuron 2003;39:749-765.
30. D'Amour KA, Gage FH. Genetic and functional differences between multipotent neuronal and pluripotent embryonic stem cells. Proc Natl Acad Sci USA 2003;30:11866-11872.
31. Chickarman V, Troein C, Nuber UA, et al. Transcriptional dynamics of the embryonic stem cell switch. PLoS Comput Biol 2006;2:1080-1092.
32. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 2003;9:15178-15183.
33. Carlin R, Davis D, Weiss M, et al. Expression of early transcription factors Oct4, Sox2 and Nanog by porcine umbilical cord (PUC) matrix cells. Reprod Biol Endocrinol 2006;4:8.
34. Katoh Y, Katoh M. Comparative genomics on SOX2 orthologs. Oncol Rep 2005;14:797-800.
35. Kuroda T, Tada M, Kubota H, et al. Octamer and Sox elements are required for transcriptional cis regulation of Nanog gene expression. Mol Cell Biol 2005;25:2475-2485.
36. Chew JL, Loh YH, Zhang W, et al. Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. Mol Cell Biol 2005;25:6031-6046.
37. Mansukhani A, Ambrosetti D, Holmes G, et al. Sox2 induction by FGF and FGFR2 activating mutations inhibits Wnt signaling and osteoblast differentiation. J Cell Biol 2005;168:1065-1076.
38. Takemoto T, Uchikawa M, Kamachi Y, et al. Convergence of Wnt and FGF signals in the genesis of posterior neural plate through activation of the sox2 enhancer N-1. Development 2006;133:297-306.
39. Korkola JE, Houldsworth J, Chadalavada RSV, et al. Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.3, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res 2006;66:820-827.
40. Rao M. Conserved and divergent paths that regulate self-renewal in mouse and human embryonic stem cells. Dev Biol 2004;275:269-286.
41. van Raag TJ, Moore KB, Iordanova I, et al. Frizzled 5 signaling governs the neural potential of progenitors in the developing Xenopus retina. Neuron 2005;46:23-36.
42. Wessels LF, van Welsem T, Hart AA, et al. Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res 2002;62:7110-7117.
43. van Beers EH, van Welsem T, Wessels LF, et al. Comparative genomic hybridization profiles in human BRCA1 and human BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res 2005;65:822-827.
44. Bergmaschi A, Kim YH, Wang P, et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 2006;45:1033-1040.
45. Palacios J, Honrado E, Osorio A, et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 2003;9:3606-3614.
46. Rodr?́guez-Pinilla SM, Sarrió D, Honrado E, et al. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol 2006, (published on-line 14 November 2006).
47. Pinilla SM, Honrado E, Hardisson D, et al. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat 2006;99:85-90.
48. Simpson PT, Gale T, Reis-Filho JS, et al. Distribution and significance of 14-3-3 sigma, a novel myoepithelial marker, in normal, benign, and malignant breast tissue. J Pathol 2004;202:274-285.
49. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310-2318.
50. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998;90:1138-1145.
51. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005;11:5175-5180.
52. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003;95:1482-1485.
53. Arnes JB, Brunet JS, Stefansson I, et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res 2005;11:4003-4011.
54. Carter MR, Hornick JL, Lester S, et al. Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. Am J Surg Pathol 2006;30:300-309.
55. Jones C, Ford E, Gillett C, et al. Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res 2004;10:5988-5997.
56. Palacios J, Honrado E, Osorio A, et al. Phenotypic characterisation of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 2005;90:5-14.
57. Leibl S, Gogg-Kammerer M, Sommersacher A, et al. Metaplastic breast carcinomas: are they of myoepithelial differentiation? Immunohistochemical profile of the sarcomatoid subtype using novel myoepithelial markers. Am J Surg Pathol 2005;29:347-353.
58. Reis-Filho JS, Milanezi F, Paredes J, et al. Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. Appl Immunohistochem Mol Morphol 2003;11:1-8.
59. Janssen EA, Baak JP, Guervos MA, et al. In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor. J Pathol 2003;201:555-561.
60. Boiani M, Scholer HR. Regulatory networks in embryoderived pluripotent stem cells. Nat Rev Mol Cell Biol 2005;6:872-884.
61. Tsukamoto T, Miroshita T, Tatematsu M. Gastric and intestinal mixed-type intestinal metaplasia: aberrant expression of transcription factors and stem cell intestinalization. Gastric Cancer 2006;9:156-166.
62. Sanada Y, Yoshida K, Konishi K, et al. Expression of gastric mucin MUC5AC and gastric transcription factor Sox2 in ampulla of vater adenocarcinoma: comparison between expression patterns and histologic subtypes. Oncol Rep 2006;15:1157-1161.
63. Tsukamoto T, Miroshita T, Mihara M, et al. Sox2 expression in human stomach adenocarcinomas with gastric and gastric-and-intestinal-mixed phenotypes. Histopathology 2005;46:649-658.
64. Sanada Y, Yoshida K, Ohara M, et al. Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor Sox2; comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components. Pancreas 2006;32:164-170.
65. Tatematsu M, Tsukamoto T, Inada K. Stem cells and gastric cancer: role of gastric and intestinal mixed intestinal metaplasia. Cancer Sci 2003;94:135-141.
66. Li XL, Eishi Y, Bai YQ, et al. Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma. Int J Oncol 2004;24:257-263.
67. Prasad NB, Biankin AV, Fukushima N, et al. Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res 2005;65:1619-1626.
68. Sattler HP, Lensch R, Rohde V, et al. Novel amplification unit at chromosome 3q25-q27 in human prostate cancer. Prostate 2000;45:207-215.
69. Bertucci F, Finetti P, Cervera N, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 2006;66:4636-4644.
70. Jones C, Nonni AV, Fulford L, et al. CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer 2001;85:422-427.
71. Letessier A, Sirconlomb F, Ginestier C, et al. Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer 2006;6:245 (in press).
72. Monaghan P, Clarke CL, Pernsinghe NP, et al. Epidermal growth factor receptor expression on human breast luminal and basal cells in vitro. Epithelial Cell Biol 1995;4:52-62.
73. van Agthoven T, Timmermaus M, Foekens JA, et al. Differential expression of estrogen, progesterone and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry. Am J Pathol 1994;144:1238-1246.
74. Korsching E, Packeisen J, Liedtke C, et al. The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis from progenitor cells with bilinear differentiation potential? J Pathol 2005;206:451-457.
75. Reis-Filho JS. Re: Korsching et al. The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol 2005;206:451-457.
76. Asselin-Labat M-L, Shackleton M, Stingl J, et al. Steroid hormone receptor status of mouse mammary stem cells. J Natl Cancer Inst 2006;98:1011-1014.